• LAST PRICE
    0.7300
  • TODAY'S CHANGE (%)
    Trending Down-0.0300 (-3.9474%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.7400 / 0.7600
  • Day Range
    Low 0.6900
    High 0.7400
  • 52 Week Range
    Low 0.2600
    High 1.1900
  • Volume
    59,000
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.76
TimeVolumeNRX
09:32 ET85000.74
09:35 ET15000.74
10:00 ET50000.74
10:06 ET5000.74
11:43 ET130000.71
11:45 ET140000.69
12:06 ET40000.71
02:05 ET40000.71
02:14 ET40000.72
02:27 ET15000.73
02:45 ET10000.74
03:30 ET20000.73
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
CanadaNRX
Nurexone Biologic Inc
53.8M
-6.6x
---
CanadaACOG
Alpha Cognition Inc
48.3M
-1.7x
---
CanadaBMND
Biomind Labs Inc
45.7M
-23.6x
---
CanadaMSCL
Satellos Bioscience Inc
88.4M
-3.2x
---
CanadaZYUS
ZYUS Life Sciences Corp
55.8M
-1.6x
---
CanadaMETX
ME Therapeutics Holdings Inc
98.2M
-22.7x
---
As of 2024-11-22

Company Information

NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.

Contact Information

Headquarters
9 Mezada Street, Bsr 3 Tower, 30 FloorBNEI BRAK, Israel 5120109
Phone
416-410-5297
Fax
416-410-5297

Executives

Chairman of the Board, Chief Executive Officer
James Richardson
Chief Financial Officer, Corporate Secretary, Director
John Arnold
Director
John-Peter Bradford
Independent Director
Peter Andrews

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$51.7M
Revenue (TTM)
$0.00
Shares Outstanding
70.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.11
Book Value
$0.01
P/E Ratio
-6.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.